TriVascular Inc. sold $1.9 million in an options offering, adding to a $40 million Series E funding round it logged last month.
Santa Rosa, Calif.-based TriVascular makes the Ovation line of stent grafts for treating abdominal aortic aneurysms.
The company sold options and convertible notes to 2 unnamed investors, according to a regulatory filing.
TriVascular closed a $40 million Series E funding round for its Ovation line of stent grafts for treating abdominal aortic aneurysms in mid-November. The company also won a humanitarian device exemption from the FDA for the Ovation device for treating patients with small iliac or femoral arteries in November 2011. Pre-market approval followed in November 2012.